Bloomberg the Company

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Follow Us

Industry Products

  • Exchange: Frankfurt
  • Sector: Health Care
  • Industry: Medical Equipment & Devices
  • Sub-Industry: Life Science Equipment

Exact Sciences Corp

+ Add to Watchlist

EXK:GR

20.515 EUR 0.042 0.21%

As of 02:56:42 ET on 02/27/2015.

Snapshot for Exact Sciences Corp (EXK)

Open: 21.151 Day's Range: 20.443 - 21.151 Volume: 50
Previous Close: 20.473 52wk Range: 7.869 - 25.186 1-Yr Rtn: +99.27%

Stock Chart for EXK

No chart data available.
  • EXK:GR 21.135
  • 1D
  • 1M
  • 1Y
20.473
Interactive EXK Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for EXK

Current P/E Ratio (ttm) -
Estimated P/E(12/2015) -
Relative P/E vs. DAX -
Earnings Per Share (USD) (ttm) -
Est. EPS (USD) (12/2015) -1.6480
Est. PEG Ratio -
Market Cap (M EUR) 1,817.28
Shares Outstanding (M) 88.58
30 Day Average Volume 343
Price/Book (mrq) -
Price/Sale (ttm) -
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement 05/01/2015
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for EXK

  • Revenue
  • Net Income (M/USD)
  • Profit Margin (%)

Company Profile & Key Executives for EXK

Exact Sciences Corp., is focused on developing and commercializing a non-invasive molecular screening test for the early detection and prevention of colorectal cancer. The Company's test is a stool-based DNA test that identifies both pre-cancer and cancer by detecting genetic mutations in colorectal cancer cells.

Kevin T ConroyChairman/President/CEOManeesh K AroraChief Operating Officer
Graham P LidgardSenior VP/Chief Science OfcrScott CowardSenior VP/General Counsel
More Company Profile & Key Executives for EXK

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil